Teachers Advisors LLC boosted its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) by 27.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,162 shares of the biopharmaceutical company’s stock after buying an additional 6,023 shares during the period. Teachers Advisors LLC owned 0.11% of Loxo Oncology worth $1,185,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. American International Group Inc. boosted its position in shares of Loxo Oncology by 27.1% in the first quarter. American International Group Inc. now owns 9,749 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 2,081 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 3,875 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Loxo Oncology by 92.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 9,200 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 6,632 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Loxo Oncology by 53.5% in the first quarter. Swiss National Bank now owns 28,700 shares of the biopharmaceutical company’s stock worth $1,208,000 after buying an additional 10,000 shares in the last quarter.

Loxo Oncology, Inc. (LOXO) traded up 0.457% during mid-day trading on Wednesday, hitting $78.115. The company had a trading volume of 55,582 shares. Loxo Oncology, Inc. has a one year low of $17.14 and a one year high of $83.12. The company’s 50 day moving average price is $73.71 and its 200-day moving average price is $57.32. The company’s market cap is $2.33 billion.

Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.99) by $0.15. During the same quarter in the previous year, the firm earned ($0.77) EPS. Equities research analysts anticipate that Loxo Oncology, Inc. will post ($4.54) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) Shares Bought by Teachers Advisors LLC” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/loxo-oncology-inc-loxo-shares-bought-by-teachers-advisors-llc/1532178.html.

A number of research analysts have recently weighed in on LOXO shares. BTIG Research restated a “buy” rating and issued a $75.00 price target on shares of Loxo Oncology in a research report on Tuesday, June 6th. Stifel Nicolaus raised their price target on Loxo Oncology from $52.00 to $71.00 and gave the company a “buy” rating in a research report on Monday, June 5th. Citigroup Inc. upgraded Loxo Oncology from a “neutral” rating to a “buy” rating and set a $86.00 price target for the company in a research report on Monday, June 5th. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price target for the company in a research report on Wednesday, August 9th. Finally, BidaskClub cut Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $70.73.

In other news, Director Lori Anne Kunkel sold 10,000 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $75.17, for a total transaction of $751,700.00. Following the completion of the transaction, the director now directly owns 16,840 shares of the company’s stock, valued at approximately $1,265,862.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Naarden Jacob Van sold 1,541 shares of Loxo Oncology stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $113,617.93. Following the transaction, the insider now directly owns 1,541 shares of the company’s stock, valued at $113,617.93. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,073 shares of company stock valued at $3,397,662. Insiders own 27.80% of the company’s stock.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.